Replies to post #72520 on Anavex Life Sciences Corp (AVXL)

[Jimbo50]

Investors should not forget about the poster titled " dose dependent therapeutic response ' the company was counselled to change the title to a generic title to eliminate any possible misinformation accusations down the road. Also , don't forget the press release that followed the poster presentation that was crafted around these 3 words " variety of doses " and yes a Rhett trial what would it cost Serepta ran a trial consisting of 13 trial patients ; not that much so good things ahead